Xortx clarifies timing for share consolidation

Calgary, alberta, nov. 10, 2023 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of november 8th, the consolidation of the company's common shares on the basis of one post-consolidation share for every nine pre-consolidation shares (the “consolidation”), will now be undertaken today with the shares expected to begin trading on a post-consolidation basis on the tsx venture exchange (“tsxv”) and the nasdaq capital market (“nasdaq”) when markets open on or about tuesday, november 14, 2023.
XRTX Ratings Summary
XRTX Quant Ranking